Xintela at partnering conferences

Xintela has worked intensively to connect the company with potential partners and international investors. Thomas Areschoug, Business Development Manager at Xintela, tells more about the conferences that the company attended during the autumn. Xintela participated in a number of partnering conferences during the autumn. First of all, why it is so important for Xintela to […]

Xintela broadens and extends patent protection for chondrocyte products and chondrocyte markers

Lund, Sweden, 8 January 2019 – Xintela announces today that the company’s international (PCT) patent application for quality-assured chondrocytes (cartilage cells), developed using the company’s integrin markers, was published on January 3, 2019 under publication number WO 2019/002547. The patent application relates to a further development of Xintela’s marker technology and quality test XACT and […]

Xintela and Catalent to co-develop brain cancer therapy

Lund, Sverige, 25 oktober 2018 – Xintela tillkännager idag att bolaget har tecknat ett samarbetsavtal med det amerikanska bolaget Redwood BioScience Inc, ett helägt dotterbolag till Catalent, Inc., världsledande inom antibody-drug conjugate (ADC) teknologi för cancerterapi. Parterna avser att gemensamt utveckla en ADC-baserad terapeutisk produkt med första inriktning på hjärntumören glioblastom, den vanligaste och mest […]

SVEN KILI TAKES ROLE AS CHIEF MEDICAL OFFICER IN XINTELA

Lund, Sweden, August 29, 2018 – Xintela AB (publ) announces today that Sven Kili extends his commitment to Xintela as Chief Medical Officer (CMO). Sven Kili, a board member and consultant to Xintela, extends his commitment to Xintela as CMO on a consultancy basis. Sven is a physician and specialist in orthopedics and, through leading […]

XINTELA TO SPIN OUT ONCOLOGY BUSINESS

Lund, Sweden, August 29, 2018 – Xintela AB (publ) announces today that the company has made the decision to spin out its oncology business to a newly formed subsidiary company, Targinta AB. The Xintela Board has decided to move the oncology business into a separate company, with plans to distribute shares to Xintela’s owners and […]

Significant progress in Xintela

Significant progress in Xintela Xintela today announces an update on the company’s development programs. Xintela develops medical products based on its patented marker technology platform XINMARK® with a focus on cell therapy and oncology. All projects have made significant progress in terms of results, patents and financing solutions so far this year. Stem cell therapy […]

Xintela extends patent protection for degenerative joint diseases

Xintela today announced that the company’s international patent application directed to the prevention and treatment of degenerative joint diseases using stem cells, including osteoarthritis, has been published. The data on which the patent application is based are derived from the horse study conducted by Xintela in late 2016. It demonstrated that stem cells, selected using […]

Newsletter no 2 2018

It is both pleasing and stimulating to look back on the intensive past six months. Our projects have shown great progress and Xintela has made significant advances. One key focus was the completion of our own GMP facility to produce stem cells for clinical trials. We opened the facility, which is located at Medicon Village […]